Novo's Wegovy Expansion Hobbled by Specialist Access Bottleneck

The immediate catalyst is clear. In January, Britain's health regulator approved a maximum dose of up to 7.2mg per week of Wegovy for patients with obesity only. This is a tactical win for Novo Nordisk, offering a potentially more effective option for its blockbuster drug. Yet the practical impact on NHS access is muted by a restrictive framework that has already proven a bottleneck.

The new dose is not a free pass. It is explicitly restricted to adult patients with obesity only, meaning those with a BMI of 30kg/m² or higher. More critically, Wegovy remains a specialist service drug, not a general practitioner prescription. As of February, Wegovy is not prescribed by GPs but instead is given by specialist NHS weight loss services. This creates a significant choke point in the rollout.

The numbers illustrate the scale of the access problem. In London alone, an estimated 500,000 residents could be eligible for these drugs. Yet as of November 2025, only 3,000 Londoners were accessing weight loss medicines on the NHS. That's a fraction of the potential pool. The recent government move to incentivize GPs with bonuses for prescribing weight-loss drugs, including Mounjaro, does not extend to Wegovy, leaving this specialist pathway intact.

The bottom line is that the MHRA's dose approval is a regulatory step forward, but it does not change the fundamental access constraints. The financial tailwind from this event is therefore delayed and limited, as the drug's availability is still governed by the slow, specialist-led rollout and strict eligibility rules.

The Incentive Mechanism: GP Payments vs. Eligibility Walls

The government's new financial push for GPs is a clear signal of intent. Starting in April, practices will receive an average £3,000 annual bonus to prescribe weight-loss drugs, with an additional £25m in ring-fenced funding for new quality indicators tracking obesity care. This is a tangible carrot aimed at accelerating access, particularly for Mounjaro.

Yet the setup creates a stark divide. The incentive applies only to Mounjaro, not Wegovy. This is a critical design flaw. It rewards GPs for prescribing a drug that is already being rolled out in primary care, while doing nothing to incentivize the prescription of Wegovy, which remains locked in the specialist pathway. The scheme, in effect, subsidizes the easier path and leaves the harder one untouched.

More fundamentally, the incentives are a blunt instrument against a wall of strict eligibility. The new GP contract indicators will track prescribing, but they do not alter the underlying clinical criteria. For Mounjaro, the threshold is being widened from a BMI over 40 to over 35 with comorbidities. For Wegovy, the bar remains high, with eligibility restricted to those with obesity only (BMI 30+). Experts are right to warn the scheme has limited impact because it does nothing to widen these strict criteria.

The bottom line is that the financial carrot is insufficient to overcome the eligibility wall. It may nudge some GPs to prescribe Mounjaro more aggressively, but it does nothing to unlock the specialist service bottleneck for Wegovy. The incentive mechanism, therefore, is a tactical move that reinforces the status quo for Novo's drug, offering no immediate relief to the access problem.

Financial Impact and Near-Term Catalysts

The financial tailwind from the policy shift is not immediate. The primary near-term catalyst is the implementation of the new GP contract in April 2026. This will test whether the £3,000 annual bonus for prescribing weight-loss drugs can drive any measurable increase in Wegovy prescriptions. Given that the incentive explicitly applies only to Mounjaro, the setup is designed to accelerate that drug's primary care rollout. For Novo, the key question is whether this financial push creates any spillover effect or simply deepens the divide between the two drugs.

A secondary catalyst is the potential rollout of community pharmacy weight management programmes for Mounjaro. This could shift patient volume into a more accessible channel, but it does not directly benefit Wegovy, which remains confined to specialist services. The government's focus on expanding access through GPs and pharmacies is therefore a double-edged sword for Novo, potentially boosting its competitor's market share while leaving its own access bottleneck intact.

The overarching risk is continued supply and access bottlenecks, as seen with the injectable version. Even if eligibility expands, the drug's uptake could be limited by the slow, specialist-led delivery model. This is not a new problem; the recent approval of a daily pill version of Wegovy in the US highlights supply issues that have previously dogged the injectable rollout. For Novo, the financial impact hinges on overcoming these operational constraints, which the current policy framework does little to address. The April contract change will show if incentives can move the needle, but the fundamental access wall remains.